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Unique obstacles to
establishing thyroid cancer
registries
The establishment of population-based cancer registries requires the
use of rigorous methodology in order to ensure complete and timely
data ascertainment [1,2]. Developing a thyroid cancer registry poses
unique obstacles that are related to the nature of the disease. Because
of the relatively indolent nature of most differentiated thyroid cancers,
there is typically a long interval between initial diagnosis and disease
recurrence, which, in turn, means that lengthy follow-up is necessary
in order to ascertain outcomes. Since differentiated thyroid cancer
confers a low risk of death, registries need to be targeted instead toward
the identiﬁcation of prognostic factors for tumor persistence and re-
currence, as has been previously comprehensively described byMehra
and colleagues regarding their proposal of a Thyroid Cancer Care Col-
laborative in the U.S. [3]. The number of known risk factors for tumor
persistence and recurrence is expanding rapidly, andmuch of the data
currently required for disease prognosis are not readily extractable from
medical records. For example, the number and size of all cervical lymph
nodes present is not a required part of the College of American Pa-
thologists’ standard pathology report [4].
We recently developed a comprehensive thyroid cancer regis-
try with the intent to capture both retrospective and prospective
individual patient data at Harvard Vanguard Medical Associates,
Boston, MA. During the timeframe of this study, this integrated health
system was comprised of 23 sites across the greater Boston area
(now even larger), connected by a robust electronic health record
(EHR) that has been in operation for nearly 40 years. Our registry
houses over 400 discrete variables related to patients’ demograph-
ics, thyroid cancer diagnosis, tumor characteristics, and the multiple
aspects of long-term thyroid cancer management, most of which
is not extractable without dedicated individual patient-level review.
As such, this type of systematic, comprehensive, and complex data
capture requires a research assistant to be trained in the speciﬁc
thyroid cancer terminology documented in the medical records for
entry into the registry tool. We look forward to taking advantage
of marketplace progress toward EHR and registry interoperability
that are envisioned under the Centers for Medicare and Medicaid
Services Meaningful Use incentive program. Our hope is to better
integrate data collection into the patient care workﬂow for basic
data, allowing research assistants to focus their data collection on
specialized data elements, such as family history, pathological staging,
and genetic markers. In comparison with the many other types of
thyroid cancer registries that have been described [3], our data-
base captures patients within an integrated multi-site institution
who reside in a discrete geographic area, collects longitudinal data
recorded in a single EHR spanning nearly 4 decades, and incorpo-
rates elements advocated in the most recent thyroid nodule and
cancer guidelines.
Data collection continues to be ongoing, and we share our ex-
perience to illustrate the complexities of designing and executing
longitudinal thyroid cancer registries, which should be developed
in a collaborative fashion. Such thyroid cancer registries need to pro-
spectively include all of the prognostic criteria advocated in themost
current thyroid nodule and cancer guidelines [5], and will need to
be plastic enough to adapt as guidelines and known risk factors
evolve. Genetic characteristics of both tumors and hosts are in-
creasingly important to clinical decision making, and may over time
change the deﬁnitions and staging of many cancers. Such regis-
tries should also include diverse patient populations in order to
produce rich, generalizable data.
Finally, the development and ongoing maintenance of such reg-
istries is an expensive endeavor. Joint partnerships with stakeholders
in academia, industry, and government ideally will be required to
fund future comprehensive thyroid tumor registries. Despite their
complexity and expense, we strongly believe that such registries
are needed, as they are able to provide a wealth of data which is
not readily available from other sources.
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